Format

Send to

Choose Destination
Leuk Lymphoma. 2017 Apr;58(4):809-815. doi: 10.1080/10428194.2016.1213824. Epub 2016 Aug 12.

[18F] Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice.

Author information

1
a Department of Haematology/Oncology , Moores Cancer Center, University of California , San Diego , CA , USA.
2
b Statistics, Genentech Inc. , South San Francisco , CA , USA.
3
c Biostatistics , RTI Health Solutions , Research Triangle Park , NC , USA.
4
d School of Medicine and Dentistry , University of Rochester , Rochester , NY , USA.
5
e Winship Cancer Institute, Emory University , Atlanta , GA , USA.
6
f Department of Medicine, Lymphoma Service , Memorial Sloan-Kettering Cancer Center , New York , NY , USA.
7
g Medical Affairs , Genentech Inc. , South San Francisco , CA , USA.

Abstract

Positron emission tomography (PET) after induction therapy in follicular lymphoma (FL) is predictive of survival in clinical trials. We describe use of PET and computed tomography (CT) after rituximab-based induction therapy in FL patients followed by the National LymphoCare Study and explore the association between imaging response assessment and survival. Among 1289 patients, imaging consisted of: PET ± CT (35%), CT alone (42%), other/no imaging (24%). Median follow-up was 7.6 years. In unadjusted analyses, positive PET ± CT and CT were prognostic of inferior OS (HR 1.78; 95% CI: 1.16-2.72 and HR 1.61, 95% CI: 1.13-2.29, respectively) and PFS (HR 1.63, 95% CI: 1.21-2.20 and HR 1.45, 95% CI: 1.12-1.89, respectively). Adjusting for FL International Prognostic Index, PET remained predictive of OS (HR 1.54, 95% CI: 1.01-2.36) and PFS (HR 1.54, 95% CI: 1.14-2.07). Residual disease via PET in FL is prognostic of survival in clinical practice.

KEYWORDS:

Follicular lymphoma; PET; prognostic; survival

PMID:
27562750
PMCID:
PMC5635823
DOI:
10.1080/10428194.2016.1213824
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center